The fight against pancreatic cancer has taken a step forward in Germany, with 120 hospitals now legally entitled to negotiate funding for OncoSil Medical’s (ASX:OSL) innovative treatment device. This marks a 43% increase from the previous year and highlights growing recognition of the OncoSil™ device within the German healthcare system.
German Hospitals Embrace OncoSil’s Innovation
Germany’s Institute for the Hospital Remuneration System (InEK) has granted hospitals the authority to negotiate reimbursement for the OncoSil™ device under the innovation funding (NUB) program. This development allows hospitals to secure funding through statutory health insurance companies, potentially improving patient access to OncoSil’s groundbreaking pancreatic cancer treatment.
“This expansion underscores the increasing demand for the OncoSil™ device in Germany,” said Nigel Lange, CEO & Managing Director of OncoSil Medical. “It is a testament to the growing confidence among healthcare professionals in the clinical benefits of our treatment.”
The company’s journey in Germany gained momentum in 2021 when OncoSil was granted a “Positive Status 1” classification under the NUB program. This designation was further strengthened in October 2024 when the German Federal Joint Committee (G-BA) approved the directive for testing OncoSil’s treatment method. By January 2025, the German Ministry of Health had officially published the Coverage with Evidence Development Study Directive in the National German Gazette.
Regulatory Milestones Strengthen Market Position
The approval from Germany’s top healthcare regulatory bodies signifies a major achievement for the OncoSil device, reinforcing its credibility and potential for widespread adoption. The latest milestone allows hospitals to engage in budget negotiations with insurers, further integrating OncoSil’s device into the country’s medical landscape.
“We remain committed to delivering life-changing solutions for patients with locally advanced pancreatic cancer,” Lange said. “With the Ministry of Health’s approval and the expanded hospital authorisation, we are well-positioned to make a meaningful impact in the German market.”
A Targeted Solution for a Critical Health Challenge
Pancreatic cancer remains one of the most challenging diseases to treat, with poor long-term survival rates and late-stage diagnoses being common. OncoSil Medical has developed a device that delivers targeted brachytherapy treatment by injecting Phosphorous-32 (32P) microparticles directly into pancreatic tumours. The procedure is performed using endoscopic ultrasound guidance alongside chemotherapy.
With regulatory clearances already in place in the European Union, the United Kingdom, Türkiye, and Israel, OncoSil is actively pursuing commercialisation of its device. Initial treatments have already commenced in Spain, Italy, and Israel, and the company continues to expand its global footprint.
Global Commercialisation Efforts Continue
While clinical trials are ongoing, OncoSil is accelerating its commercial strategy, focusing on high-growth markets where pancreatic cancer treatment options are limited. The company’s device has already received breakthrough designation in key markets, including the EU, UK, and the US, further supporting its global rollout.
“Our vision is to ensure patients worldwide have access to innovative treatments,” Lange said. “This latest development in Germany is a key milestone in our broader commercialisation strategy.”
As OncoSil strengthens its foothold in Germany, investors will be watching closely to see how the company leverages its latest regulatory win to drive adoption and revenue growth in 2025 and beyond.
Latest posts by Gracen Moore (see all)
1 Comment
Shraddha13
Thank you for sharing! To explore further
Replyhttps://www.360iresearch.com/library/intelligence/pancreatic-cancer-therapeutics